MiNK Therapeutics, Inc.
INKT
Last
$10.72
Day
-3.1%
1y
-24.4%
5y
-90.8%
52w
-35.0%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1334d
EMA 21
11.82
EMA 50
11.69
EMA 200
11.57
20d high
-15.3%
5y high
-95.0%
5y range
3th
Positions held
Your positionsINKT isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
17
Hold
watch
Signal
Neutral
Target
$12.96
Stop
$10.02
Stop distance
6.5%
Target vs last
+20.9%
Fundamentals
| Market cap | $56.13M | Enterprise value | $47.33M | Trailing P/E | — | Forward P/E | -4.16 |
| PEG | — | Price / book | -4.00 | Beta | 0.47 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | -123.8% | Debt / equity | — |
| Current ratio | 1.23 | Free cash flow | -$5.35M | Analyst recommendation | strong_buy | Mean target | $39.00 |
| 52w high | $16.93 | 52w low | $8.48 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$3.1M | -$2.7M | -$2.6M | -$2.9M | -$4.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.2M | -$2.9M | -$3.3M | -$3.0M | -$3.7M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$12.5M | -$10.8M | -$22.5M | -$28.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$12.5M | -$10.7M | -$22.9M | -$30.9M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
2026-08-14 · MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript
2026-08-14 · MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-13 · MiNK Therapeutics Inc (INKT) (Q2 2026) Earnings Call Highlights: AGENT-797 Shows Early Promise ...
2026-08-13 · MiNK Therapeutics Q2 Earnings Call Highlights
2026-07-16 · Here's Why You Should Add INKT Stock to Your Portfolio Now
Price (daily)
Full chart · RSI · MACD · patternsINKT · daily-9.2% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin